AstraZeneca

Request for Proposal (RFP) for an Independent Medical Education Grant

Therapeutic Area:	Transthyretin amyloidosis including hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) and hereditary transthyretin amyloid mixed phenotype (ATTRv-CM with ATTRv-PN)
Focus:	Expand disease awareness, including recognition of disease characteristics to prompt early diagnosis, current and emerging clinical data for treatment of ATTRv, and care plans to benefit patients with ATTRv.
Recommended learning format:	Live, Virtual Live with Audio and/or Video plus Enduring Component; Certified Education Credit for the Target Audience. Optional formats may include: podcasts, panel discussions, simulations, patient case studies and/or print
Recommended target audience:	Neurologists/neuromuscular-peripheral neuropathy, Primary Care Physicians, Nurses, Advanced Practice and Specialty Pharmacists, Cardiologists/heart failure, Geneticists
Program Anticipated Start Date:	January 15, 2027 through July 31, 2027
Final Grant Decision:	Grants will be reviewed and approved on a rolling basis.
RFP reference code:	CGA_ATTRv Amyloidosis_2027
Submission Information & links:	grants@astrazeneca.com (email communication) www.astrazenecagrants.com Donna Maier, PhD, Associate Director, Medical Education and Grants Office, donna.maier@astrazeneca.com

The Request:

We welcome submissions for independent medical education grants (IME/CME) from educational providers who believe they can meet the high standards of grant submission and deployment of virtual independent medical education. Submitted applications should include a formal letter of request and grant proposal with needs assessment, learning objectives, agenda, and budget schedule.

AstraZeneca, Medical Education Grants Office (MEGO):

AstraZeneca is committed to supporting quality independent medical education that meets an educational need by providing information to healthcare professionals to improve patient care and outcomes. We support education that furthers the understanding of emerging therapies based on a documented unmet need, support the efforts of health care professionals to broaden patient knowledge and awareness of disease states and treatment options, and support the efforts of healthcare professionals to broaden

patient knowledge and awareness of disease states and treatment. Our grant support is focused within areas of high unmet need that overlap with our medical areas of interest. For more information, please visit www.astrazenecagrants.com